Are Skin Lesion Analyzers Ready for Prime Time? FDA panel not fully on board to reclassify computer-aided melanoma detection devices Jul 30, 2022
TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression More than a fifth of patients responded to lenvatinib-pembrolizumab combination Jul 26, 2022
Something Fishy About Tuna and Melanoma Risk Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
Case: VEGFR Inhibition in Merkel Cell Carcinoma Patient Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
FDA Issues Orders Clarifying Rules for Marketing Sunscreens But more studies on sunscreen chemicals are still needed, advocacy group says Sep 24, 2021
In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor? Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
COVID Surges Emerge; FDA Warns About Chantix; Lions, Tigers, Bears Get Vaxxed A daily roundup of news on COVID-19 and the rest of medicine Jul 06, 2021
Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
Lymph Node Findings on PET: Cancer or COVID Vaccine? Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
Bad Day Sunshine: Benzene Found in Many Sun Care Products Valisure also detected the carcinogen in hand sanitizers earlier this year May 26, 2021
Novel Immunotherapy Boosts Melanoma Outcomes Adding LAG-3 checkpoint inhibitor to nivolumab extended PFS in patients with advanced disease May 19, 2021
Doubling Down on Immunotherapy in Advanced Melanoma Checkpoint inhibitor combo active after upfront anti-PD-1/L1 therapy May 09, 2021
Nivolumab Alone Prevails in Resected Melanoma Adding ipilimumab in adjuvant setting failed to improve relapse-free survival Apr 11, 2021
A Win for Adjuvant Immunotherapy in Esophageal Cancer And other highlights from the Society of Surgical Oncology's virtual 2021 meeting Mar 31, 2021
Want Data on Recently Approved Actinic Keratosis Drug? Here You Go Phase III trial now published in full for topical anti-proliferative treatment Feb 10, 2021
First Immunotherapy Approved for Basal Cell Carcinoma Objective responses in 27% of previously treated patients who received cemiplimab Feb 10, 2021
IL-8 Antibody Active in Tumors After PD-1/L1 Blockade Clinical benefit in more than a third of patients with anti-IL-8/nivolumab combo Nov 13, 2020
PD-1 Inhibitor Active in Progressive Basal Cell Cancer Response rate of 20-30% with cemiplimab after post-hedgehog inhibitor progression or intolerance Nov 11, 2020
Melanoma Survival Benefit Sustained at 5 Years With Adjuvant Combo Dabrafenib plus trametinib cut relapse risk in half Sep 02, 2020
Demographics Make a Difference in Common Skin Cancers Study looks at epidemiology of basal versus squamous cell carcinomas Aug 26, 2020
Calcineurin Blockers for Eczema: No Cancer Signal in Big Study "Clinicians can use this evidence to counsel and reassure patients" Aug 12, 2020
Triplet OK'd as First-Line Therapy in Melanoma Immunotherapy plus targeted combo nets FDA approval in BRAF-mutant population Jul 31, 2020
Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
Biologics Don't Increase Melanoma Risk... Probably Meta-analysis offers some reassurance, but leaves room for doubt May 20, 2020
Face-Aging Selfies Help Modify Risky Skin Behaviors for Teens Trial looked at effects of a free "UV-selfie" app May 07, 2020
6-Week Keytruda Safe, Effective in Melanoma Schedule gets FDA approval for all adult indications Apr 30, 2020
Triplet Succeeds in BRAF-Mutant Melanoma Immunotherapy plus BRAF/MEK inhibition boosts PFS over targeted agents alone Apr 27, 2020
